Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge

Atsushi Hirano, Arihiko Kanehiro, Katsuichiro Ono, Wataru Ito, Akio Yoshida, Chiharu Okada, Hiromi Nakashima, Yasushi Tanimoto, Mikio Kataoka, Erwin W. Gelfand, Mitsune Tanimoto

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-β1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-β1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.

Original languageEnglish
Pages (from-to)366-377
Number of pages12
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume35
Issue number3
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Inflammation
Airway Remodeling
Ovalbumin
Bronchoalveolar Lavage Fluid
Transforming Growth Factors
Goblet Cells
Interleukin-13
Platelet-Derived Growth Factor
Interleukin-5
Fluids
Lymphocytes
Eosinophils
Interleukin-4
Allergens
Immunoglobulin E
Hyperplasia
Therapeutics
Asthma
pirfenidone
Lung

Keywords

  • Airway hyperresponsiveness
  • Airway inflammation
  • Airway remodeling
  • Pirfenidone

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology

Cite this

Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. / Hirano, Atsushi; Kanehiro, Arihiko; Ono, Katsuichiro; Ito, Wataru; Yoshida, Akio; Okada, Chiharu; Nakashima, Hiromi; Tanimoto, Yasushi; Kataoka, Mikio; Gelfand, Erwin W.; Tanimoto, Mitsune.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 35, No. 3, 09.2006, p. 366-377.

Research output: Contribution to journalArticle

Hirano, A, Kanehiro, A, Ono, K, Ito, W, Yoshida, A, Okada, C, Nakashima, H, Tanimoto, Y, Kataoka, M, Gelfand, EW & Tanimoto, M 2006, 'Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge', American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 3, pp. 366-377. https://doi.org/10.1165/rcmb.2005-0452OC
Hirano, Atsushi ; Kanehiro, Arihiko ; Ono, Katsuichiro ; Ito, Wataru ; Yoshida, Akio ; Okada, Chiharu ; Nakashima, Hiromi ; Tanimoto, Yasushi ; Kataoka, Mikio ; Gelfand, Erwin W. ; Tanimoto, Mitsune. / Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. In: American Journal of Respiratory Cell and Molecular Biology. 2006 ; Vol. 35, No. 3. pp. 366-377.
@article{2996d163759a46c9990c209a0063380c,
title = "Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge",
abstract = "We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-β1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-β1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.",
keywords = "Airway hyperresponsiveness, Airway inflammation, Airway remodeling, Pirfenidone",
author = "Atsushi Hirano and Arihiko Kanehiro and Katsuichiro Ono and Wataru Ito and Akio Yoshida and Chiharu Okada and Hiromi Nakashima and Yasushi Tanimoto and Mikio Kataoka and Gelfand, {Erwin W.} and Mitsune Tanimoto",
year = "2006",
month = "9",
doi = "10.1165/rcmb.2005-0452OC",
language = "English",
volume = "35",
pages = "366--377",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge

AU - Hirano, Atsushi

AU - Kanehiro, Arihiko

AU - Ono, Katsuichiro

AU - Ito, Wataru

AU - Yoshida, Akio

AU - Okada, Chiharu

AU - Nakashima, Hiromi

AU - Tanimoto, Yasushi

AU - Kataoka, Mikio

AU - Gelfand, Erwin W.

AU - Tanimoto, Mitsune

PY - 2006/9

Y1 - 2006/9

N2 - We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-β1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-β1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.

AB - We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-β1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-β1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling.

KW - Airway hyperresponsiveness

KW - Airway inflammation

KW - Airway remodeling

KW - Pirfenidone

UR - http://www.scopus.com/inward/record.url?scp=33748470700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748470700&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2005-0452OC

DO - 10.1165/rcmb.2005-0452OC

M3 - Article

C2 - 16675785

AN - SCOPUS:33748470700

VL - 35

SP - 366

EP - 377

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 3

ER -